SMAD3 and myeloproliferative disorder: Combined JAK1/2 and SMAD3 treatment proved to be the most efficient in preventing the myelofibrosis induced by BM-MSCs via neoplastic MPN mononuclear cells regardless of the presence of JAK2 mutation.